Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-C5) – HRP

SARS-CoV-2 Nucleocapsid (N) Protein

This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. <b> (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)</b>

This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.

Ships Overnight on Blue Ice

Anti-SARS-CoV-2 Nucleocapsid, clone NP1-C5, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Furthermore, it is reported to bind to the RNA binding domain of the N protein.

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the Coronaviridae family, and its single-stranded, positive-sense RNA genome shares 79.6% identity with SARS-CoV¹. The spike (S), envelope (E), membrane (M), and nucleocapsid proteins (N) are four essential structural proteins of SARS-CoV-2². The 46 kDa N protein is highly conserved and shares 90% homology with SARS-CoV³. Similar to SARS-CoV, SARS-CoV-2 has an N-terminal (NTD) and C-terminal domain (CTD), linked by a linker region. The NTD binds to RNA, while the CTD self-oligomerizes^4,5, aiding viral genome packaging into a helical ribonucleoprotein complex⁶. The N protein also participates in viral transcription, replication, and modulation of cell signaling pathways^7,8. Some vaccine and diagnostic assays⁹ have focused on the N protein as it is highly expressed during infection and activates antibodies^3,10 and memory T cells^11,12, found in convalescent sera. The N-protein also evades the innate immune system by inhibiting RNAi¹³, identifying it as a potential therapeutic target.

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.